View on Pubmed.gov 40768678 | View on doi.org 10.1200/PO-24-0...
Impact of Baseline β-Catenin Comutations on Prognosis in EGFR-Mutant Lung Cancer.
- Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Bavarian Cancer Research Center (BZKF), National Center for Tumor Diseases (NCT) WERA, Würzburg, Germany.
- Institute of Pathology, University of Würzburg, Würzburg, Germany.
- Department of Thoracic Oncology, Thoraxklinik, Heidelberg University Hospital and National Center for Tumor Diseases (NCT), NCT Heidelberg, a Partnership Between DKFZ and Heidelberg University Hospital, Heidelberg, Germany.
- Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany.
- Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
- Department of Internal Medicine II, Medical Oncology, University Hospital Würzburg, Würzburg, Germany.
- Klinikum Würzburg Mitte, Missioklinik, Medizinische Klinik-Schwerpunkt Pneumologie und Beatmungsmedizin, Würzburg, Germany.
- Department of Internal Medicine I, Pneumology, University Hospital Würzburg, Würzburg, Germany.
- Comprehensive Cancer Center Augsburg, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
Abstract
PURPOSE
Epidermal growth factor receptor (EGFR) mutations are a main actionable driver in non-small cell lung cancer (NSCLC). However, the clinical significance of catenin beta-1 (CTNNB1) comutations remains unclear. This study evaluated outcomes of patients with EGFR/CTNNB1 comutated NSCLC in a dual-center cohort.
METHODS
A retrospective analysis of 1,804 patients with NSCLC undergoing next-generation sequencing (NGS) in 2019-2024 at University Hospital Würzburg (single-center cohort, including 15 patients with EGFR/CTNNB1 comutations) was complemented with patients with EGFR/CTNNB1 comutated NSCLC receiving first-line osimertinib at the Thoraxklinik Heidelberg (n = 11) to extend and validate initial findings. We assessed clinical outcomes after first-line osimertinib therapy in 90 EGFR-mutated patients with CTNNB1 wild-type (wt) status and 23 with CTNNB1 comutation.
RESULTS
CTNNB1 mutations were identified in 2.0% (36/1,804) of all patients with NSCLC from the single-center cohort, with 41.7% of these also harboring EGFR mutations. Among EGFR-mutant tumors, 7.7% (15/195) exhibited concurrent CTNNB1 mutations. In the dual-center cohort, the objective response rate with first-line osimertinib was 74.4% in CTNNB1-wt (n = 90) and 65.0% in CTNNB1-mutant patients (n = 23; P = .38). Notably, CTNNB1 mutations were associated with significantly longer progression-free survival (PFS; hazard ratio [HR], 0.32; P < .001) and overall survival (OS; HR, 0.33; P = .003). Multivariate analysis confirmed CTNNB1 comutation as an independent prognostic factor for improved PFS (HR, 0.31 [95% CI, 0.14 to 0.69]; P = .004) and OS (HR, 0.26 [95% CI, 0.10 to 0.65]; P = .004). Additionally, CTNNB1 mutations correlated with lower PD-L1 expression (P = .001) and TP53-wt status (P < .001).
CONCLUSION
CTNNB1 comutations are associated with lower PD-L1 expression and TP53-wt status, correlating with improved outcomes in patients with EGFR-mutant NSCLC undergoing osimertinib therapy. These results suggest that CTNNB1 comutations may serve as a favorable prognostic biomarker in patients with EGFR-mutant NSCLC. Additional prospective studies are warranted to validate these results.
References
Clin Lung Cancer. 2022 May;23(3):264-272
J Thorac Oncol. 2015 Jan;10(1):93-101
Eur J Cancer. 2024 Mar;199:113556
Control Clin Trials. 1996 Aug;17(4):343-6
Conflict of interest statement
MeSH
- •
- •
- •
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
- •
- •
Substances
- •
- •
- •
- •
- •
- •
- •
- •